Erivedge Efficacy Overcomes Limitations Of Single-Arm Study
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Response rates of 30%-43% and a 7.6-month median duration of response were sufficiently clinically meaningful to allow FDA approval of Genentech’s basal cell carcinoma treatment on the basis of a non-randomized study.